Citius Oncology (CTOR) AI Stock Analysis

• Market Cap: $66.54M
• Dividend Yield: N/A
• Average Volume (3M): 2.48M
• Price to Earnings (P/E): 3.2
• Beta (1Y): -0.47
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Financial
• Sector Strength: 82
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.27
• Shares Outstanding: 71,552,400
• 10 Day Avg. Volume: 7,307,823
• 30 Day Avg. Volume: 2,479,837
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.00
• Price Target Upside: 248.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Citius Oncology faces significant challenges with poor financial performance characterized by net losses and negative cash flows, indicative of its developmental stage in the pharmaceutical industry. Despite an attractive valuation due to a low P/E ratio, technical analysis suggests bearish trends. The absence of recent earnings call insights or significant corporate events further underscores the high-risk nature of the stock.

Positive Factors

Market Expansion

Citius Oncology plans to expand Lymphir's indications to peripheral T cell lymphoma and broader immune oncology, which presents additional growth opportunities.

Market Readiness

The commercial readiness of Lymphir is underway, with existing therapies generating significant revenues, indicating a receptive market for new treatments.

Negative Factors

Market Competition

Lymphir is targeting the IV-targeted therapy segment of the CTCL market, which usually comes after progression on oral systemics and chemotherapies.

Citius Oncology Business Overview & Revenue Model

Company Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

How the Company Makes Money

Citius Oncology makes money primarily through the development and commercialization of its proprietary oncology treatments. The company generates revenue by licensing its drug candidates to larger pharmaceutical companies, forming partnerships for co-development and commercialization, and through direct sales of approved therapies. Key revenue streams include milestone payments from licensing agreements, royalties from product sales, and research and development funding from strategic partnerships. Additionally, CTOR may receive grants and financial support from government agencies or non-profit organizations dedicated to cancer research.

Citius Oncology Financial Statement Overview

Summary

Citius Oncology's financial performance is characterized by consistent net losses and lack of revenue, reflective of its developmental stage. Balance sheet volatility and negative cash flows highlight financial instability and liquidity challenges, necessitating strategic management.

Income Statement

Citius Oncology shows a challenging income situation with consistent net losses over the reported periods. The absence of revenue and gross profit highlights the early-stage nature or restructuring phase of the company. Despite some improvement in EBIT from 2023 to 2024, the overall profitability metrics remain weak, given the negative net income.

Balance Sheet

The balance sheet reveals high volatility with fluctuating stockholders' equity and liabilities. Although there is a significant increase in assets from 2023 to 2024, the negative equity in some periods and inconsistent asset base pose stability concerns. The absence of debt could indicate cautious financing, but the negative equity ratios in some periods showcase financial vulnerability.

Cash Flow

Cash flow statements show inconsistent operating cash flows and negative free cash flow, indicating liquidity challenges. The reliance on financing activities to support cash flows is evident, but the lack of consistent positive cash flow from operations could hinder growth prospects. The free cash flow growth rate is negative, which poses a risk for future financial health.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00
	EBIT
0.00	-20.57M	-12.12M	-4.86M
	EBITDA
-6.39M	-20.57M	-12.12M	-4.86M
	Net Income Common Stockholders
-6.66M	-21.15M	-12.70M	-5.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
289.18K	112.00	0.00	0.00
	Total Assets
68.19M	84.37M	47.73M	42.69M
	Total Debt
0.00	3.80M	0.00	0.00
	Net Debt
-289.18K	3.80M	0.00	0.00
	Total Liabilities
31.84K	38.23M	22.20M	6.42M
	Stockholders Equity
68.16M	46.14M	25.54M	36.27M
Cash Flow		Free Cash Flow
-364.06K	-4.87M	0.00	0.00
	Operating Cash Flow
-364.06K	126.35K	0.00	0.00
	Investing Cash Flow
-22.55K	-5.00M	0.00	0.00
	Financing Cash Flow
353.65K	4.87M	0.00	0.00

Citius Oncology Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Neutral. The current price of 0.86 is above the 20-day moving average (MA) of 0.76, below the 50-day MA of 1.03, and below the 200-day MA of 4.17, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 50.97 is Neutral, neither overbought nor oversold. The STOCH value of 43.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTOR.

Citius Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$14.35B	9.94	8.94%	4.37%	16.34%	-11.76%
CTOR	46 Neutral	$66.54M	3.19	-34.78%	―	―	―
ADAP	46 Neutral	$50.42M	―	-273.36%	―	194.23%	45.50%
AFMD	42 Neutral	$11.01M	―	-151.46%	―	-95.23%	-325.89%
MRUS	41 Neutral	$2.91B	―	-42.88%	―	-17.78%	-10.95%
KPTI	36 Underperform	$31.48M	―	41.08%	―	-0.55%	49.85%